License: Allianz- bzw. Nationallizenz PDF - Published Version (95kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-376463
- DOI to cite this document:
- 10.5283/epub.37646
Abstract
Background: Since 2010, combination therapy with gemcitabine and cisplatin is the standard treatment for patients with biliary tract cancer (BTC) based on the ABC-02 trial. However, treatment after first-line progression is less clearly defined. We therefore retrospectively analyzed the efficacy of a 3-drug chemotherapy regimen in patients with advanced BTC. Methods: Patients with advanced BTC ...
Owner only: item control page